Related Experiment Video
Updated: Jan 26, 2026

Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment
Published on: April 19, 2024
Heart rate variability in type 2 diabetic subjects randomized to liraglutide or glimepiride treatment, both in
Thomas Nyström1, Irene Santos-Pardo1, Xin Fang2
1Department of Clinical Science and Education Södersjukhuset Karolinska Institutet Stockholm Sweden.
Insights
Liraglutide increased daytime heart rate (HR) in type 2 diabetes patients, without affecting heart rate variability (HRV) or autonomic nervous system activity. This study compared liraglutide to glimepiride for cardiovascular risk parameters.
Area of Science:
- Cardiology
- Endocrinology
- Pharmacology
Background:
- Reduced heart rate variability (HRV) and increased heart rate (HR) are linked to cardiovascular mortality.
- The Liraglutide Effect and Action in Diabetes trial showed fewer cardiovascular events with liraglutide in type 2 diabetes (T2D) patients.
Purpose of the Study:
- To compare the effects of liraglutide versus glimepiride on HR and HRV in T2D patients.
- To assess liraglutide's impact on cardiovascular risk parameters.
Main Methods:
- A post hoc study involving 62 T2D patients randomized to liraglutide or glimepiride, both with metformin.
- 24-hour Holter monitoring assessed HR, sympathetic activity (SDNN), and parasympathetic activity (RMSSD, HF, LF power).
Main Results:
- Liraglutide treatment led to a persistent increase in diurnal HR and a significant increase in daytime HR (5.4 bpm, P=0.011).
- No significant differences were observed between groups in SDNN, RMSSD, HF, or LF power.
Conclusions:
- Liraglutide increased diurnal HR variation and mean daytime HR.
- These HR changes occurred independently of alterations in sympathetic or parasympathetic activity.
Aims:
Reduced heart rate variability (HRV) and increased heart rate (HR) are associated with cardiovascular (CV) mortality. In the Liraglutide Effect and Action in Diabetes outcome trial, it was demonstrated a lower rate of CV events in type 2 diabetes (T2D) patients treated with liraglutide compared to placebo. We aimed to investigate the effects of liraglutide compared with glimepiride treatment in T2D patients on the CV risk parameters HR and HRV.
Methods:
This was a post hoc study whereas sixty-two T2D individuals (45 males) were randomized to once daily 1.8 mg liraglutide or once daily 4 mg glimepiride, both in combination with 1 g metformin. HR and measurement of sympathetic activity, that is standard deviation (SD) of beat-to-beat (NN) intervals (SDNN), was assessed by 24-hour Holter monitoring system. Parasympathetic activity was analysed by root mean square of successive differences (RMSSD) in NN intervals and high-frequency (HF), low-frequency (LF) and very low-frequency power.
Results:
Baseline clinical characteristics for liraglutide (n = 33) and glimepiride (n = 29) groups were well matched. There was a persistent increase in diurnal HR followed by a significantly increased HR at daytime 5.4 beats per minute, P = 0.011 in the liraglutide-treated group. There was no treatment change between groups in SDNN and RMSSD, or in HF and LF frequency power analysis.
Conclusions:
Liraglutide treatment increased diurnal variation in hourly mean HR followed by an increase in mean daytime HR, independently of changes in sympathetic or parasympathetic activity.
Related Concept Videos
Random Variables
Uppercase letters such as X or Y denote a random variable. Lowercase letters like x or y denote the value of a random variable. If X is a random variable, then X is written in words, and x is given as a number.
For example, let X = the...
Bioequivalence Experimental Study Designs: Completely Randomized and Randomized Block Designs
Random Error
Randomized Experiments
Simple randomization
Simple...
Random and Systematic Errors
Diabetes Mellitus: Type 2 and Gestational

